drugset
drugset / Trial / NCT04268706

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

NCT04268706 ↗

Phase 2 Active not recruiting 97 enrolled Tessa Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.

Timeline

Start
2021-02-01
Primary completion
2025-05
Completion
2037-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CD30.CAR-T Cell therapy — Intravenous
Background Bendamustine Small molecule 70 mg/m2 —
Background Fludarabine Small molecule 30 mg/m2 —

Indications

classic Hodgkin lymphoma